China Biopharmaceuticals Names New Officer and Directors

China Biopharmaceuticals Holdings, Inc.
2007-05-08 10:19 627

Ms. Zhang Jian named Chairwoman of the Board

Mr. Shi Mingsheng appointed Chief Operating Officer

Mr. Ding Weihua appointed to the Board of Directors

BEIJING, May 7 /Xinhua-PRNewswire-FirstCall/ -- China Biopharmaceuticals Holdings, Inc. (OTC Bulletin Board: CHBP), a leading pharmaceutical company focused on the development, manufacturing and marketing of innovative drugs in China, today announced that Ms. Zhang Jian has been elected Chairwoman of the board of directors, Mr. Shi Mingsheng has been named Chief Operating Officer, and Mr. Ding Weihua has been appointed to the Board of Directors. All appointments were made as of April 30, 2007.

Ms. Zhang Jian has served as the General Manager of Suzhou Erye Pharmaceutical Company Limited ("Erye") since 2003. Prior to being the General Manager for Erye, she served for more than 5 years as the deputy general manager of Suzhou Number 2 Pharmaceutical Company and more than a year as the deputy general manager of Suzhou Number 4 Pharmaceutical Company after working in various positions in charge of human resources and quality control there. Ms. Zhang has extensive background and experience in the pharmaceuticals industry having worked in various managerial positions and various aspects of the industry. She is an expert in managing a growth company, having turned Erye into a successful operation after taking it over from the government with Mr. Shi Mingsheng. She will be overseeing the Company's strategic growth and have responsibility for all operations.

Mr. Shi Mingsheng has been named Chief Operating Officer of CHBP. He has served as the Chairman of Suzhou Erye Pharmaceutical Company Limited ("Erye") since 2003. He has helped Ms. Zhang Jian to build a successful and profitable business which currently has a joint venture with China Biopharmaceuticals.

Mr. Ding Weihua was elected to the board of directors of the Company. Mr. Ding is a veteran in the pharmaceuticals industry having worked in the field for more than thirty three years. Mr. Ding worked nine years as a Deputy General Manager and Manager in sales and marketing at Erye. Prior to his positions in Erye, he worked six years in business planning at Jiangsu Nantong Qinfen Pharmaceutical Company. Later he worked sixteen years at Suzhou Number 2 Pharmaceutical Company in sales before he was promoted to the position of Manager of Sales and Deputy General Manager.

"These new appointments not only add depth to our management team but demonstrate our commitment to enhancing our corporate governance. The experience that all three members bring from our most successful subsidiary to date, Eyre, will have an immediate positive impact on the management and performance of China Biopharmaceuticals," stated Mr. Chris Peng Mao, Chief Executive Officer of China Biopharmaceuticals.

Mr. Mao continued, "Ms. Zhang Jian's and Mr. Ding Weihua's strong background and understanding of the pharmaceutical industry make them a valuable addition to our board of directors. I am also thrilled to have Mr. Shi Mingsheng join our team as Chief Operating Officer. His extensive operational experience will help ensure that our Company is run efficiently and profitably. Their contributions will add tremendous value to our team as we continue moving our business forward."

About China Biopharmaceuticals Holdings, Inc.

China Biopharmaceuticals Holdings, Inc (Symbol: CHBP) is a vertically integrated pharmaceutical company dedicated to the discovery, development, manufacturing and marketing of small and large molecule pharmaceutical products, including medicines, vaccines, and active pharmaceutical ingredients for various categories of diseases. CHBP's product portfolio includes 260 drugs already approved for manufacturing and marketing by the Chinese State Food and Drug Administration (SFDA). CHBP also has submitted 15 drug applications to the SFDA for its review during the calendar year of 2006. CHBP is a U.S.-listed public company with operating subsidiaries and senior management based in China. For further information, please visit our website at .

Safe Harbor Statement

The statements contained herein that are not historical facts are "forward looking statements" within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Such forward-looking statements may be identified by, among other things, the use of forward-looking terminology such as "believes," "expects," "may," "will," "should," or "anticipates" or the negative thereof or other variations thereon or comparable terminology, or by discussions of strategy that involve risks and uncertainties. In particular, our statements regarding the potential growth of the markets are examples of such forward- looking statements. The forward-looking statements include risks and uncertainties, including but not limited to, general economic conditions and regulatory developments, not within our control. The factors discussed herein and expressed from time to time in our filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed or implied by such statements. The forward looking statements are made only as of the date of this filing, and we undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Source: China Biopharmaceuticals Holdings, Inc.